Nosis Bio Principal Scientist to give Selected Talk at 2023 Annual Oligotherapeutics Society Meeting

Nosis Biosciences was honored to be selected to present at the 2023 Annual Oligotherapeutic Society meeting, where we will showcase groundbreaking data on our receptor-targeted approach to cell- and gene-specific oligotherapeutics. This recognition highlights our innovative strides in developing oligotherapeutics that precisely target pathogenic cells, opening new possibilities for treating complex diseases through precision-targeted genetic medicines. Nosis Bio Principal Scientist Dr. Kyler Lugo will present this work and be available for discussions after his talk.

In tandem, Nosis is actively pursuing strategic collaborations with pharmaceutical partners to accelerate the development of cell-specific RNA medicines. Through our proprietary Nosis Connexa platform, we aim to advance a new class of RNA therapeutics that precisely target pathogenic cells while minimizing off-target effects. By joining forces with industry leaders, we seek to combine our expertise in physics-aware deep learning and molecular design with our partners’ capabilities, ultimately driving breakthroughs in RNA medicine and delivering transformative therapies to patients in need.

‍